ES2348263T3 - Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 011 de pseudomonas aeruginosa. - Google Patents

Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 011 de pseudomonas aeruginosa. Download PDF

Info

Publication number
ES2348263T3
ES2348263T3 ES06706900T ES06706900T ES2348263T3 ES 2348263 T3 ES2348263 T3 ES 2348263T3 ES 06706900 T ES06706900 T ES 06706900T ES 06706900 T ES06706900 T ES 06706900T ES 2348263 T3 ES2348263 T3 ES 2348263T3
Authority
ES
Spain
Prior art keywords
monoclonal antibody
human monoclonal
antibody
human
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06706900T
Other languages
English (en)
Spanish (es)
Inventor
Adrian Zuercher
Michael P. Horn
Alois B. Lang
Martin A. Imboden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenta Biotech AG
Original Assignee
Kenta Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech AG filed Critical Kenta Biotech AG
Application granted granted Critical
Publication of ES2348263T3 publication Critical patent/ES2348263T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES06706900T 2005-02-14 2006-02-13 Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 011 de pseudomonas aeruginosa. Expired - Lifetime ES2348263T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003095A EP1690875A1 (en) 2005-02-14 2005-02-14 Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
EP05003095 2005-02-14

Publications (1)

Publication Number Publication Date
ES2348263T3 true ES2348263T3 (es) 2010-12-02

Family

ID=34933741

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06706900T Expired - Lifetime ES2348263T3 (es) 2005-02-14 2006-02-13 Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 011 de pseudomonas aeruginosa.

Country Status (11)

Country Link
US (1) US8197816B2 (https=)
EP (2) EP1690875A1 (https=)
JP (1) JP4944799B2 (https=)
KR (2) KR20070107756A (https=)
CN (1) CN101120018B (https=)
AT (1) ATE480563T1 (https=)
CA (1) CA2597701C (https=)
DE (1) DE602006016736D1 (https=)
ES (1) ES2348263T3 (https=)
IL (1) IL184774A (https=)
WO (1) WO2006084758A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571673A1 (en) * 2004-06-28 2006-01-05 Proteome Systems Intellectual Property Pty Ltd Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor
EP2417157A1 (en) * 2009-04-09 2012-02-15 Kenta Biotech AG Human monoclonal antibody specific for lipolysaccarides (lps) of serotype lats 01 of pseudomonas aeruginosa
KR20120128686A (ko) * 2010-02-18 2012-11-27 심포젠 에이/에스 녹농균의 혈청형 ａ 지질다당류에 대한 항체
EP2361989A1 (en) * 2010-02-26 2011-08-31 Kenta Biotech AG Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits
CA2925897A1 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
EP4512826A3 (en) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimeric protein complexes and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
JP4398620B2 (ja) 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
EP1319025A2 (en) * 2000-09-07 2003-06-18 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse

Also Published As

Publication number Publication date
EP1690875A1 (en) 2006-08-16
JP2008530988A (ja) 2008-08-14
DE602006016736D1 (de) 2010-10-21
KR20070107756A (ko) 2007-11-07
ATE480563T1 (de) 2010-09-15
IL184774A0 (en) 2007-12-03
EP1848741A1 (en) 2007-10-31
US20090068191A1 (en) 2009-03-12
EP1848741B1 (en) 2010-09-08
KR20130018991A (ko) 2013-02-25
JP4944799B2 (ja) 2012-06-06
CA2597701A1 (en) 2006-08-17
CN101120018B (zh) 2012-07-25
CN101120018A (zh) 2008-02-06
IL184774A (en) 2012-01-31
US8197816B2 (en) 2012-06-12
CA2597701C (en) 2012-01-10
WO2006084758A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
TWI785583B (zh) 一種抗新型冠狀病毒的單克隆抗體及其應用
AU2018392741B2 (en) Antibodies to tumour antigens
ES2361269T3 (es) Anticuerpos especificos de tgf beta 1.
ES2994374T3 (en) Antibody molecule-drug conjugates and uses thereof
IL184774A (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
ES2338105T3 (es) Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa.
US20120114657A1 (en) Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
CN109879966A (zh) 基于鼠源cd19抗体的人源化设计及表达验证
CN118063612B (zh) 抗ror1抗体或其抗原结合片段及其用途
CN116710146A (zh) 抗体分子-药物偶联物及其用途
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途
JP2024526154A (ja) フィブロネクチン－インテグリン相互作用及びシグナル伝達を検出及び調節するための組成物及び方法
WO2023221892A1 (zh) 抗α-Synuclein抗体及其用途
CN115819581A (zh) 一种靶向人cd47的抗体、制备方法和应用
CN111040033A (zh) 靶向肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用
HK1148555A (en) Pseudomonas aeruginosa outer membrane protein pa4710